Wisit Cheungpasitporn
1*, Charat Thongprayoon
2, Supavit Chesdachai
3,4, Jackrapong Bruminhent
41 Department of Internal Medicine, Division of Nephrology, University of Mississippi Medical Center, Jackson, Mississippi, USA
2 Department of Internal Medicine, Bassett Medical Center, Cooperstown, NY, USA
3 Department of Medicine, University of Minnesota, Minnesota, USA
4 Department of Medicine, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Thailand
Implication for health policy/practice/research/medical education:
BK polyomavirus-associated nephropathy (BKVAN) is an important cause of allograft renal
dysfunction after kidney transplantation. Recent evidence has suggested associations of
BK infection with urological malignancies and the development of de novo donor specific
antibody (DSA). Despite recent advances in kidney transplantation knowledges, management
of BKVAN has remained challenges. Recent evidence has suggested that BK-specific T-cell
responses, but not neutralizing antibodies, is important in clearance of BK viremia. In this
article, we present future directions in prevention and treatment of BKVAN.
Please cite this paper as: Cheungpasitporn W, Thongprayoon C, Chesdachai S, Bruminhent
J. Future directions in the treatment of BK virus nephropathy. J Nephropharmacol.
2018;7(1):3-5. DOI: 10.15171/npj.2018.02.